Coronary Artery Disease Clinical Trial Landscape

The coronary artery disease trial landscape in 2026

Coronary artery disease remains the world's leading cause of death and one of the most heavily resourced areas of cardiovascular clinical development. With statins and PCSK9 inhibitors managing LDL-C, the current frontier has shifted to residual inflammatory risk (colchicine, IL-6 inhibitors), elevated Lp(a) (siRNA and ASO approaches), and — most commercially exciting — GLP-1/GIP receptor agonists demonstrating direct cardioprotective effects beyond weight loss.

The LEADER, EMPA-REG OUTCOME, and now SURPASS-CVOT trials established that metabolic agents reduce MACE independent of glucose control. Novo Nordisk's SELECT trial (semaglutide in non-diabetic CVD patients) reset the cardiovascular indication landscape for GLP-1s. Now, the race is on to determine which mechanism — Lp(a) lowering, targeted anti-inflammation, or next-generation incretin therapy — delivers the next cardiovascular outcomes blockbuster.

Key CAD program categories to monitor:

• Lp(a) reduction: Pelacarsen (AKCEA-APO(a)-LRx, HORIZON outcomes trial), olpasiran, zerlasiran — the most watched outcomes studies in CV right now
• Residual inflammatory risk: Colchicine, canakinumab successors, IL-6 pathway inhibitors, and NF-κB-targeting approaches
• GLP-1/GIP in CVD: Semaglutide and tirzepatide extension into non-diabetic CAD populations, heart failure prevention studies
• PCSK9 combination approaches: Inclisiran (siRNA) combinations, novel PCSK9 inhibitor formulations
• Coronary imaging and physiology: HeartFlow FFR-CT, IVUS-guided intervention, intravascular imaging outcome studies
• Cell/gene therapy for CAD: Early-phase programs targeting angiogenesis, cardiac repair after MI

What DataLookout monitors for CAD

Configure your profile with keywords as specific or broad as your intelligence needs require. Examples:

• By condition subtype: "stable coronary artery disease", "acute coronary syndrome", "STEMI", "chronic coronary syndrome"
• By mechanism: "Lp(a) CAD", "IL-6 coronary artery disease", "GLP-1 cardiovascular", "PCSK9 inhibitor CAD"
• By intervention type: "coronary revascularization", "PCI coronary artery", "CABG outcomes", "stent CAD"
• Phase filter: Phase 3 outcomes trials for MACE readouts, or all phases for complete pipeline visibility

Who uses CAD trial monitoring

Cardiovascular BD and strategy teams

Companies with cardiovascular franchises monitor the CAD clinical landscape for competitive intelligence and in-licensing opportunities. The Lp(a) space is particularly active, with multiple Phase 3 outcomes trials in progress from AstraZeneca (pelacarsen via AKCEA), Amgen (olpasiran), and Silence Therapeutics (zerlasiran). Understanding which program is furthest along and what their enrollment is progressing affects BD valuations and competitive strategy.

Medtech and device companies

Abbott, Boston Scientific, Medtronic, and emerging coronary imaging companies (HeartFlow, ACIST Medical) monitor device and imaging trials continuously. The HeartFlow ADVANCE trial studying FFR-CT-guided revascularization is one of the more commercially consequential CAD device trials in 2026. Medtech BD teams use daily trial monitoring to track competitive interventional programs.

Cardiovascular investors and analysts

Analysts covering cardiovascular therapeutics use Phase 3 initiations and enrollment updates as leading indicators. An Lp(a)-lowering outcomes trial hitting enrollment milestones earlier than expected, or a GLP-1 combination entering a large Phase 3 CAD outcomes study, can precede material valuation events.

Current CAD trial activity (as of early 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

The Lp(a) outcomes trial race is the most consequential cardiovascular clinical story of 2026. Pelacarsen (AstraZeneca/Novartis, HORIZON trial), olpasiran (Amgen, OCEAN[a]-OUTCOMES), and zerlasiran (Silence Therapeutics) are all running Phase 3 MACE outcomes studies. The first positive Lp(a) outcomes trial would create a new blockbuster category — cardiovascular guidelines currently lack any Lp(a)-targeting recommendation despite Lp(a) affecting 20% of the global population.

The GLP-1 cardioprotection story continues to expand. Following SELECT (semaglutide in obese non-diabetic CAD patients), multiple programs are exploring incretin agents in CAD populations without metabolic indication — including heart failure prevention, post-MI remodeling prevention, and stable CAD risk reduction. Novo Nordisk has multiple registered Phase 3 trials in CAD-adjacent settings.

Frequently asked questions